NS-863 Low Dose

Phase 2Small molecule

NS Pharma

NS-863 Low Dose is one of 83 small molecule programs targeting Interstitial Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Interstitial Lung DiseaseActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

Interstitial Lung DiseasePhase 2

Active, not recruiting

Pulmonary Arterial HypertensionPhase 2

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Pulmonary Arterial Hypertension

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

6 2

Reata

Biogen

Phase 3

1 3

Levitra

Bayer

Phase 3

1 4

Aurlumyn

BBTG International Inc.

Phase 3

8 5

Flolan

Johnson & Johnson

Phase 3

1 6

Zesly

MMezzion Pharma Co. Ltd

Phase 3

1 7

Inhaled Iloprost

Bayer

Phase 3

1 8

Atrovent

MS Contin

1 10

Rituxan

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

Pulmonary Arterial Hypertension

NCT07441200

Phase 2Not yet recruiting

Interstitial Lung Disease

NCT07441278

Clinical

Trials by Indication[1]

Pulmonary Arterial Hypertension1 trial

Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)

Not yet recruiting· NS Pharma logo

NS Pharma·Phase 2·NCT07441200·135 enrolled

Interstitial Lung Disease1 trial

A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Not yet recruiting· NS Pharma logo

NS Pharma·Phase 2·NCT07441278·177 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NS-863 Low Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NS-863 Low Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NS-863 Low Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NS Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NS Pharma

NS-863 Low Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Pulmonary Arterial Hypertension1 trial

Interstitial Lung Disease1 trial

References

Drug Info

Quick Facts

Related News